231 related articles for article (PubMed ID: 12473588)
1. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma.
Ohishi Y; Oda Y; Uchiumi T; Kobayashi H; Hirakawa T; Miyamoto S; Kinukawa N; Nakano H; Kuwano M; Tsuneyoshi M
Clin Cancer Res; 2002 Dec; 8(12):3767-75. PubMed ID: 12473588
[TBL] [Abstract][Full Text] [Related]
2. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
[TBL] [Abstract][Full Text] [Related]
3. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response.
Materna V; Pleger J; Hoffmann U; Lage H
Gynecol Oncol; 2004 Jul; 94(1):152-60. PubMed ID: 15262134
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Akeshima R; Sato S; Kamazawa S; Takahashi M; Kanamori Y; Suzuki M; Ohwada M; Terakawa N
Oncology; 2002; 62(4):349-53. PubMed ID: 12138243
[TBL] [Abstract][Full Text] [Related]
5. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
Burger H; Foekens JA; Look MP; Meijer-van Gelder ME; Klijn JG; Wiemer EA; Stoter G; Nooter K
Clin Cancer Res; 2003 Feb; 9(2):827-36. PubMed ID: 12576456
[TBL] [Abstract][Full Text] [Related]
6. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas.
Hinoshita E; Uchiumi T; Taguchi K; Kinukawa N; Tsuneyoshi M; Maehara Y; Sugimachi K; Kuwano M
Clin Cancer Res; 2000 Jun; 6(6):2401-7. PubMed ID: 10873092
[TBL] [Abstract][Full Text] [Related]
8. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
Canet B; Pons C; Espinosa I; Prat J
Hum Pathol; 2011 Jun; 42(6):833-9. PubMed ID: 21208644
[TBL] [Abstract][Full Text] [Related]
9. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract.
Zimmermann C; Gutmann H; Hruz P; Gutzwiller JP; Beglinger C; Drewe J
Drug Metab Dispos; 2005 Feb; 33(2):219-24. PubMed ID: 15523049
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin.
Tada Y; Wada M; Migita T; Nagayama J; Hinoshita E; Mochida Y; Maehara Y; Tsuneyoshi M; Kuwano M; Naito S
Int J Cancer; 2002 Apr; 98(4):630-5. PubMed ID: 11920626
[TBL] [Abstract][Full Text] [Related]
11. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma.
König J; Hartel M; Nies AT; Martignoni ME; Guo J; Büchler MW; Friess H; Keppler D
Int J Cancer; 2005 Jun; 115(3):359-67. PubMed ID: 15688370
[TBL] [Abstract][Full Text] [Related]
12. [Expression and prognostic value of the drug resistance markers P-gp, Mrp1, Mrp2, and Lrp in ovarian carcinoma].
Katsaros D; Fracchioli S; Arts HJ; de Vries EG; Danese S; Richiardi G; Arisio R; Gordini G; Van der Zee AG; Suurmeijer AJ; Massobrio M
Minerva Ginecol; 1999 Dec; 51(12):463-70. PubMed ID: 10767994
[TBL] [Abstract][Full Text] [Related]
13. Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer.
Obata H; Yahata T; Quan J; Sekine M; Tanaka K
Anticancer Res; 2006; 26(3B):2227-32. PubMed ID: 16821592
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer.
Sedláková I; Laco J; Caltová K; Červinka M; Tošner J; Řezáč A; Špaček J
Int J Gynecol Cancer; 2015 Feb; 25(2):236-43. PubMed ID: 25594141
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels.
Young LC; Campling BG; Cole SP; Deeley RG; Gerlach JH
Clin Cancer Res; 2001 Jun; 7(6):1798-804. PubMed ID: 11410522
[TBL] [Abstract][Full Text] [Related]
16. Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis.
Faggad A; Darb-Esfahani S; Wirtz R; Sinn B; Sehouli J; Könsgen D; Lage H; Noske A; Weichert W; Buckendahl AC; Budczies J; Müller BM; Elwali NE; Dietel M; Denkert C
Histopathology; 2009 May; 54(6):657-66. PubMed ID: 19438741
[TBL] [Abstract][Full Text] [Related]
17. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.
Surowiak P; Materna V; Kaplenko I; Spaczynski M; Dolinska-Krajewska B; Gebarowska E; Dietel M; Zabel M; Lage H
Clin Cancer Res; 2006 Dec; 12(23):7149-58. PubMed ID: 17145840
[TBL] [Abstract][Full Text] [Related]
18. Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy.
Larbcharoensub N; Leopairat J; Sirachainan E; Narkwong L; Bhongmakapat T; Rasmeepaisarn K; Janvilisri T
Hum Pathol; 2008 Jun; 39(6):837-45. PubMed ID: 18400250
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic significance of Pgp, MRP1, and MRP3 in ovarian cancer patients].
Sedláková I; Laco J; Tošner J; Špaček J
Ceska Gynekol; 2015 Dec; 80(6):405-13. PubMed ID: 26741154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
